Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus axitinib for unresectable or metastatic non-clear cell renal cell carcinoma
jRCT1061200062Completed
- Start
- Aug 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of pembrolizumab and axitinib in non-clear cell renal cell carcinoma (nccRCC) and renal cell carcinoma (RCC). Primary endpoint: Overall response rate. Started Aug 2021; status: completed.
02
Drugs
pembrolizumabaxitinib
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on jRCT1061200062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1061200062.